Daniel Simon

Daniel Simon currently serves as the Chief Business Officer at IDEAYA Biosciences and is a Lifesciences Advisory Council Member at Pear VC. With a robust background in business development, Daniel has held significant roles including Senior Consultant at Tachyon Therapeutics and Chief Business Officer at REVOLUTION Medicines, where responsibilities included strategic planning, portfolio analysis, and companion diagnostic strategies. Previously, Daniel held senior positions at Guardant Health, MyoKardia, and Onyx Pharmaceuticals, contributing to corporate development and strategy. An MBA with a healthcare major from The Wharton School complements Daniel’s academic foundation, which began with a Natural Sciences degree from the University of Cambridge.